(AP) - The federal government is approving a treatment for multiple sclerosis patients with a severe intestinal disorder.
The Food and Drug Administration has cleared Tysabri for use in patients with moderate to severe Crohn's disease who don't respond to more conventional drugs.
Government officials say patients must undergo an educational program on the drug's risks and can only receive the injectable drug from a select number of registered physicians.
The approval represents a comeback for Tysabri. It was temporarily pulled from the market in 2005 after three patients using the drug developed a rare nervous system disorder.
The FDA allowed the drug back on the market the following year under a restricted distribution program. It's used by more than 12,000 multiple sclerosis patients in the U.S.
Email
Facebook
Google
Twitter
Favorites
More
Advertisement